WO2019103660A1 - Méthode de traitement de la sclérose en plaques (et variantes) - Google Patents
Méthode de traitement de la sclérose en plaques (et variantes) Download PDFInfo
- Publication number
- WO2019103660A1 WO2019103660A1 PCT/RU2018/050142 RU2018050142W WO2019103660A1 WO 2019103660 A1 WO2019103660 A1 WO 2019103660A1 RU 2018050142 W RU2018050142 W RU 2018050142W WO 2019103660 A1 WO2019103660 A1 WO 2019103660A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- somatotropin
- igf
- multiple sclerosis
- treatment
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 34
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 58
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 58
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims abstract description 45
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims abstract description 44
- 230000037396 body weight Effects 0.000 claims abstract description 39
- 239000000411 inducer Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 12
- 229960003161 interferon beta-1b Drugs 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- -1 for example Polymers 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 239000000122 growth hormone Substances 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241000700198 Cavia Species 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101800001586 Ghrelin Proteins 0.000 description 3
- 102400000442 Ghrelin-28 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000007542 Paresis Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960000794 baclofen Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000005495 thyroid hormone Substances 0.000 description 3
- 229940036555 thyroid hormone Drugs 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 102400000321 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000718541 Tetragastris balsamifera Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229960003938 moxonidine Drugs 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical class NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ORXSOQFSAQHWSR-UHFFFAOYSA-N 3-phenyl-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C1=CC=CC=C1 ORXSOQFSAQHWSR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000022846 Abnormality of vision Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100021713 Nuclear nucleic acid-binding protein C1D Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- a present invention relates to medicine, in particular to methods of therapy and/or prophylaxis of multiple sclerosis (MS) by introducing growth hormone (somatotropin) and/or somatomedin C (IGF-1) or their physiological inducers to a subject who needs it.
- MS multiple sclerosis
- Myelin is a multi-layered plasma membrane that forms the myelin sheath around nerve fibers, in particular around oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system, around neuronal axons, which acts as an electrical isolator, which increases the speed of a nerve impulse.
- the destruction of the myelin sheath consisting of lipids for approximately 70% and of proteins for approximately 30%, leads to the occurrence of sclerosis and autoimmune diseases.
- MS Multiple sclerosis
- MS is a chronic autoimmune disease that affects the myelin sheath of nerve fibers due to the immune system attack on the Central nervous system.
- myelin damage lesion formation (demyelination) of the white matter of the brain and spinal cord, the conductivity of signals between nerve cells is disturbed.
- MS is a multifactorial disease, in the pathogenesis of which both external factors, such as viral infections, and internal, namely genetic predisposition, can be involved.
- the etiology of MS is still not clear, which is an obstacle to the development of etiotropic treatment.
- Clinical manifestations of MS are evaluated using the subject’s condition scales, assessing the severity of symptoms of lesions of brain various conductive systems and the degree of disability, such as the functional systems state (FSS) scale and the expanded disability status scale (EDSS) (Kurtzke JF (1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology 33 (11): 1444-1452; Collins et al. A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Mult Scler. 2016 Sep; 22(10): 1349–1358).
- FSS functional systems state
- EDSS expanded disability status scale
- RS remittent-relapsing
- SPMS secondary progressive
- PPMS primary progressive
- PRMS progressive recurrent
- Symptoms of MS are diverse and manifest during periods of relapse with a gradual progressive depletion of neurological functions. Symptoms can be expressed by muscle weakness, a violation of the coherence of muscle movements (ataxia) of the body and limbs, paresis, tremor, and abnormality of vision functions. Often, a decrease in sensitivity is observed, including without clear localization, dysfunction of the pelvic organs, decreased intelligence, depression, and behavioral disorders. The first clinical symptoms of multiple sclerosis usually appear in patients between the ages of 18 and 45, although the debut of MS is described for both children and the elderly.
- WO 2010/128035 discloses the use of GM-CSF (granulocyte macrophage colony-stimulating factor) antibody or its receptor in the treatment or prophylaxis of multiple sclerosis.
- GM-CSF granulocyte macrophage colony-stimulating factor
- the introduction of antibodies to GM-CSF to the patient leads to a decrease in the proliferation of T-cells, the release of IL-17 (interleukin-17) from them.
- WO 2010/147665 discloses a method of reducing the frequency of relapses and reducing the development of physical disability in remittent-relapsing MS (RRMS) by daily oral administration of 0.6 mg of laquinimod, which is a derivative of phenylquinolone.
- WO 2017165367 describes a method for inducing remyelination for the treatment of RRMS using a composition containing siRNA (small interfering RNA) that inhibits the activity, synthesis or expression of a protein associated with low density lipoprotein 1 (LRP1).
- siRNA small interfering RNA
- Betaferon from Bayer Pharma AG for the treatment of multiple sclerosis is known containing recombinant human interferon- ⁇ -1b.
- a fairly low efficiency of its use is the disadvantage of this drug – only 30% decrease in the frequency of exacerbations of the disease and their severity is observed, as well as the presence of such side effects as the increase of depressive symptomatology (Sokolova E. S., Totolyan N. A., Klimenko V. M. Psycho-emotional changes in patients with multiple sclerosis after the treatment by Betaferon // "Stress and behavior", VII Interdisciplinary conference on biological psychiatry, Novosibirsk, 2003).
- Copaxone immunomodulatory drug from Teva is known containing glatiramer acetate as the active substance, which is a polymer of four sinistrorotatory isomers of acetates of synthetic polypeptides glutamine, lysine, alanine and tyrosine. Copaxon does not show advantages in the treatment of primary progressive and secondary progressive multiple sclerosis.
- the author of a present invention has unexpectedly discovered that active substances such as somatotropin and immunoglobulin growth factor 1 (IGF-1, also referred to as somatomedin C) can be used to effectively treat multiple sclerosis, and in quantities that exceed the amount of these substances that were considered acceptable for administration to patients.
- IGF-1 immunoglobulin growth factor 1
- the author has found that the task of the invention is solved in the same way when using physiological inducers of somatotropin and/or IGF-1.
- the relief of symptoms, reducing the frequency of recurrence and stimulation of regeneration of neuronal myelin membranes is understood here as the treatment of multiple sclerosis, i.e., all that has beneficial effects on the course of the disease in a subject.
- the present invention makes it possible to carry out the treatment of multiple sclerosis effectively, but at the same time providing the necessary safety in terms of the occurrence and/or severity of side effects.
- Somatotropin also called somatotropic hormone or growth hormone
- Somatotropin is a pituitary growth hormone with a molecular weight of about 22 kDa and 191 amino acid residues. Somatotropin is necessary for postnatal growth and for the normalization of carbohydrate, lipid, nitrogen and mineral metabolism.
- somatotropin secretion of somatotropin is affected by a number of substances, including protein food, some amino acids, such as arginine, lysine, ornithine and glutamine, clofelin, moxonidine, baclofen, estrogens, dopamine, intestinal hormones, such as releasing growth hormone peptides (GHRP) and ghrelin, serotonin, amphetamine, propranolol, glucagon, thyroid hormones, vasopressin and others.
- GHRP growth hormone peptides
- IGF-1 a protein similar to insulin.
- IGF-1 consists of 70 amino acid residues, has a molecular mass of 7.6 kDa and enters the blood mainly from the liver, and its secretion is stimulated by somatotropin. It is known that IGF-1 has a direct regulating effect on hematopoiesis, especially lymphopoiesis and the functioning of the immune system (Clark P., 1997), stimulates the differentiation and transition of pro-B-to pre-B cells (Landgreth K.
- IGF-1 secretion is affected by substances such as glutamine, arginine, angiotensin-II, baclofen, ghrelin, thyroid hormones, somatotropin, sterilglucosides (SG), such as acylated steril- ⁇ -glucosides (ASG) and others.
- substances such as glutamine, arginine, angiotensin-II, baclofen, ghrelin, thyroid hormones, somatotropin, sterilglucosides (SG), such as acylated steril- ⁇ -glucosides (ASG) and others.
- a method of treating multiple sclerosis comprising administering of somatotropin to a subject who needs it in a therapeutically effective amount.
- a method for treating multiple sclerosis including the introduction of insulin-like growth factor 1 (IGF-1) in a therapeutically effective amount to a subject who needs it.
- IGF-1 insulin-like growth factor 1
- a method of treating multiple sclerosis comprising administering a physiological inducer of somatotropin and/or of IGF-1 in therapeutically effective amount to a subject who needs it.
- the invention encompasses the use of somatotropin as a medication for treating multiple sclerosis in a subject, the use of IGF-1 as a medication for treating multiple sclerosis in a subject, and finally the use of a physiological inducer of somatotropin and/or IGF-1 as a medication for the treatment of multiple sclerosis in a subject.
- the invention relates to the use of somatotropin and/or IGF-1 and/or their physiological inducers for the manufacture of a medication for the treatment and/or prophylaxis of multiple sclerosis or its selected symptoms.
- the applied amount of somatotropin according to the invention may be, for example, from 0.05 to 0.5 IU/kg of the body weight of a subject.
- the applied amount of IGF-1 according to the invention may be, for example, from 50 to 500 ⁇ g/kg of the body weight of a subject.
- the preferred regimen of administration of somatotropin, IGF-1, as well as their physiological inducers may be one or two times a day for 10-60 days. It should be noted that, depending on the therapeutic advisability, other doses and regimen of administration can be chosen.
- the active substances according to the invention are administered, as a rule, in the form of a pharmaceutical composition having a dosage form suitable for the desired administration.
- the methods and active substances of the invention can be used in combination to treat the same subject, for example, somatotropin, IGF-1, and one or more of their physiological inducers can be administered to the subject in any combination as one combined composition or in several compositions separately.
- the introduction of somatotropin, IGF-1 or their physiological inducers may be accompanied by the additional introduction of interferon- ⁇ -1b, in particular recombinant human interferon- ⁇ -1b.
- recombinant human interferon- ⁇ -1b is administered in amounts of from 33 to 330 mg/kg of the body weight of a subject; the regimen of administration may correspond with the regimen of introduction of somatotropin, IGF-1 and their physiological inducers, preferably once or twice a day for 10-60 days.
- inducer refers to a molecule that stimulates the expression of genes that are in an inactive state. Inducers can also function by binding to activators. In the absence of an inducer, activators, as a rule, weakly bind to DNA, whereas during the formation of the complex of activator and inducer, the activity of the latter increases many times, after which such complex binds to the activated sequence and triggers the transcription of the target gene.
- GHRP growth hormone
- SG sterilglucosides
- ASG acylated steril- ⁇ -glucosides
- peptide refers to a polymer of amino acids, regardless of the length of the polymer; thus, protein fragments, oligopeptides and proteins are included in the definition of a peptide or polypeptide.
- This term also does not define or does not exclude post-expression modifications of polypeptides, for example, polypeptides, which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are uniquely covered by the term “polypeptide”.
- This definition also includes polypeptides that contain one or more amino acid analogs (including, for example, non-naturally occurring amino acids, amino acids that are found in nature only outside an unrelated biological system, modified amino acids from mammalian systems, etc.), polypeptides with substituted bonds, as well as other modifications known in this field, both natural and non-natural.
- amino acid analogs including, for example, non-naturally occurring amino acids, amino acids that are found in nature only outside an unrelated biological system, modified amino acids from mammalian systems, etc.
- treatment refers to therapeutic treatment, prophylactic or preventative measures for research and diagnostic applications.
- treatment refers to reversion, alleviating, inhibiting the progression or preventing a disorder or a state in relation to which the term is used, or one or more symptoms of such a disorder or a state.
- the term covers a full range of therapies for the specific state from which a subject suffers, e.g., the introduction of active substance or composition containing it, to alleviate or relieve symptoms or complications; the delay of the state progression, partial relief of disease or disorder clinical implications; cure or elimination of a state, disease or disorder and/or prevention or reduction of the risk of developing a state, disease or disorder.
- prevention or “prophylaxis” mean a system of measures and patient care to prevent the development of a state, disease or disorder and imply the administration of active compounds to prevent or reduce the risk of the appearance of symptoms or complications.
- administration when applied to biological objects, such as an animal, human, experimental subject, cell, tissue, organ or biological fluid, refers to bringing into contact an exogenous pharmaceutical, therapeutic agent, diagnostic agent or composition with a biological object, including an animal, a human, a subject, a cell, a tissue, an organ or a biological fluid.
- administration may refer, for example, to therapeutic, pharmacokinetic, diagnostic, research and experimental methods.
- Treatment of cells involves bringing the reagent into contact with the cell, as well as bringing the reagent into contact with the fluid medium where the fluid medium is in contact with the cell.
- administration also means methods of cells treatment in vitro and ex vivo, for example, by reagent, diagnostic means, binding compound or other cell.
- autoimmune disease is understood in its usual meaning, and refers to a disease developed as a result of an immune response against one's own tissues or tissue components, including both humoral immune response and cell-mediated responses.
- subject refers to any mammal, including rodents, such as a mouse or rat, guinea pigs and primates, such as the Javanese macaque (Masas fascicularis), the rhesus monkey (Masas mulatta) or humans (Homo sapiens).
- rodents such as a mouse or rat
- guinea pigs and primates such as the Javanese macaque (Masas fascicularis), the rhesus monkey (Masas mulatta) or humans (Homo sapiens).
- rodents such as a mouse or rat
- guinea pigs and primates such as the Javanese macaque (Masas fascicularis), the rhesus monkey (Masas mulatta) or humans (Homo sapiens).
- a subject is a primate, most preferably a human.
- terapéuticaally effective dose or “therapeutically effective amount” or “pharmaceutically effective dose” or “pharmaceutically effective amount” means the dose that has the effects for which it is administered.
- a therapeutic agent is administered in an amount effective to alleviate one or more disease or state of a patient or population to be treated, either by inducing regressions of these diseases or states, or by inhibiting the progression of such diseases or states in any clinically measurable degree.
- composition refers to a mixture containing one or more active substances in accordance with the present invention together with other components, in particular physiologically/pharmaceutically acceptable excipients.
- the pharmaceutical composition should have a compound optimized for the desired route of administration of the active ingredient into the body and, ultimately, demonstration of the biological action.
- “Pharmaceutical” or “pharmaceutically acceptable” refers to chemical compounds and compositions that do not lead to nect side, allergic or other adverse reaction when administered to a mammal, in particular a human, or such reactions are minimized.
- a pharmaceutically acceptable excipient is a non-toxic solid, soft or liquid filler, diluent, capsule material or other additive substance of any type.
- pharmaceutically acceptable salt refers to the salt formed by the compounds used in the present invention, and an acid or base, which is suitable for inclusion in the composition of the drug.
- Pharmaceutically acceptable salts include inorganic and organic salts.
- the preferred types of salts are salts formed by the compounds according to the present invention and an acid.
- Suitable salt-forming acids include: inorganic acids, such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, and the like; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid, and the like, but are not limited to.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, ni
- salts formed by the compounds of the present invention and bases for example, alkali metal salts (for example, sodium or potassium salts), alkaline earth metal salts (for example, calcium or magnesium salts), ammonium salts (for example, ammonium salts lower alkanols or other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylene diamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts and amine salts formed with morpholine, piperazine and lysine.
- alkali metal salts for example, sodium or potassium salts
- alkaline earth metal salts for example, calcium or magnesium salts
- ammonium salts for example, ammonium salts lower alkanols or other pharmaceutically
- “Pharmaceutically acceptable carrier” means one or more compatible solid, semi-solid or liquid excipients that are suitable for administration to a subject and must have sufficient purity and sufficiently low toxicity. "Compatibility” in this document means that the components of the composition can be mixed with compounds according to the invention or with each other, and they will not significantly reduce the effectiveness of compounds.
- Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween®), a humectant (such as sodium dodecyl sulfate), dyes and flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
- cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
- gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose
- prodrug refers to peptides that are rapidly transformed in vivo to form the basic compound of the above formulas, for example, by hydrolysis in the blood or by metabolism in cells, such as, for example, cells of the basal ganglia.
- prodrugs include pharmaceutically acceptable nontoxic esters of compounds of the present invention.
- Compound esters of the present invention can be obtained by usual methods: «March's Advanced Organic Chemistry, 5th Edition» M. B. Smith & J. March, John Wiley & Sons, 2001.
- Somatotropin, IGF-1 or their inducers are administered usually in the form of a pharmaceutical composition.
- the invention also relates to a pharmaceutical composition for the treatment and/or prophylaxis of multiple sclerosis, containing somatotropin.
- the invention relates to a pharmaceutical composition for the treatment and /or prophylaxis of multiple sclerosis containing IGF-1.
- the invention also relates to a composition comprising one or more physiological inducers of somatotropin and/or IGF-1.
- Pharmaceutical compositions or substances according to the invention may contain pharmaceutically acceptable excipients, including carriers, diluents, adjuvants, etc. Examples of excipients are well known in the art and, for example, are described in Remington: The Science procurement Practice of Pharmacy, 20th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2000.
- compositions of the invention can be produced in various ways, in accordance with techniques well known to a person skilled in the art, for example, from Remington: The Science and Practice of Pharmacy (Lippincott Williams & Wilkins; Twenty first Edition, 2005), WO 1993025222, WO 1990011070, EU 1991462959.
- Pharmaceutically acceptable excipients that can be used are, in particular, described in the Handbook of Pharmaceuticals Excipients, American Pharmaceutical Association (Pharmaceutical Press; 6th revised edition, 2009).
- the pharmaceutical composition of the invention contains somatotropin and/or IGF-1 and/or one or more physiological inducers of somatotropin and/or IGF-1 in an amount effective to provide therapy of multiple sclerosis (MS), in particular, to reduce and/or slow down the rate of disability in MS.
- the composition according to the invention further comprises a recombinant human interferon- ⁇ -1b in a therapeutically effective amount.
- composition according to the invention can be carried out in various ways, including, without limitation, the oral, subcutaneous, intravenous, parenteral, intranasal, intraortical, intraocular, rectal, vaginal, transdermal, intraperitoneal, intramuscular, intrapulmonary, or intrathecal route of administration.
- composition according to the invention can be administered in parallel with other therapeutic agents, i.e., therapeutic agents described herein can be administered in parallel, simultaneously or sequentially with other pharmacotherapeutic agents or in the setting of other therapeutic effects on the body, such as radiation therapy, physiotherapy, surgery, etc.
- Any of the active substances included in the compositions according to the invention can be administered indirectly by introducing exogenous nucleic acid, for example DNA or RNA encoding the corresponding active substance, which results in the introduced nucleic acid expression.
- compositions of the invention are given a drug form suitable for the desired route of administration.
- the composition of the invention is in a solid form, including capsules, tablets, pills, powders, and granules.
- the active compounds are mixed with at least one conventional inert excipient, for example, with any of the following components: (a) a filler or agent that improves compatibility, such as starch, lactose, sucrose, glucose, mannitol or salicylic acid: (b) binders, for example hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) a humectant, such as glycerin; (d) disintegrating agents such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain mixed silicates and sodium carbonate; (e) dissolution retardants, such as paraffin; (e) absorption accelerators, for example, quaternary ammonium compounds; (g) plasticizers, such as cetyl alcohol
- Solid dosage forms such as tablets, capsules, pills and granules may contain coatings and shells such as intestinal-soluble coatings and any other materials known in the field. They can contain an opaque agent. The release of active compounds or compounds from compositions may be delayed in a certain part of the digestive tract. Examples of encapsulants include polymers and waxes. If necessary, the active compounds and one or more of the above excipients can form microcapsules.
- a solid pharmaceutical composition according to the invention can be made in the form of a lyophilizate suitable for obtaining a liquid preparation for injection (intramuscular, subcutaneous, etc.) or oral administration.
- Liquid dosage forms may, for example, be a solution or suspension of one or more of these compounds and optionally be the pharmaceutical adjuvants in a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like.
- a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like.
- the pharmaceutical composition for administration may also contain other non-toxic excipients such as wetting or emulsifying agents, pH buffering agents, etc. Typical examples of such excipients are sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc.
- solutions of peptides according to the present invention are used in a sterile aqueous solution, in aqueous propylene glycol or in sesame or peanut oil.
- Aqueous solutions should be suitably buffered when appropriate, and the liquid diluent must be made isotonic, for example, using an appropriate saline solution or glucose.
- Aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. All used sterile water mediums can be easily obtained by standard methods known to experts in the field.
- Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
- solid carriers are lactose, magnesia, sucrose, cyclodextrin, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
- liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene, and water.
- the carrier or diluent may include any sustained-release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with wax.
- the pharmaceutical compositions obtained by combining the compounds used in the present invention and pharmaceutically acceptable carriers can then be easily administered in various dosage forms suitable for the described routes of administration. Preparations may, for convenience, be provided in a standard dosage form using methods known in the pharmaceutical field.
- the active substances of the invention formulated into a pharmaceutical composition can be enclosed in microcapsules, for example, from the poly(lactic-co-glycolic acid) (PLGA), as well as in liposomes or virus-like particles, etc.
- PLGA poly(lactic-co-glycolic acid)
- Somatotropin for use in the invention can be obtained by any known method; may be of natural or synthetic origin. The most convenient way is the use of recombinant somatotropin (rhGH), methods for producing which are well known, for example from US 8178108.
- rhGH recombinant somatotropin
- Somatotropin can be presented in any modification, in which the activity of the hormone is preserved and at the same time the preferential properties are given.
- somatotropin can be in the form of complexes, in particular, in a complex with zinc.
- Another modification includes somatotropin conjugates with polymers, such as with polyethylene glycol.
- hybrid somatotropin containing additional domains can be used, for example, facilitating the delivery of protein to the target, for example, somatotropin-transferrin fusion protein.
- various somatotropin isoforms may be used. In the present description and in the claims, all of these options are covered by the term "somatotropin", "growth hormone", etc..
- IGF-1 can also be a protein of natural or synthetic origin, for example, recombinant IGF-1, the production method of which is known, for example, from US5262308.
- IGF-1 can be a complex, conjugate, hybrid, isomorph, in which case the activity is preserved and additional preferential properties appear. In this description and in the claims of the invention, all these options are covered by the term "IGF-1", "somatomedin C", etc.
- Physiological inducers of somatotropin and/or IGF-1 can be obtained by known methods, chemical or microbiological, and equally can be obtained from natural sources, which also applies to amino acids, in particular lysine, arginine and glutamine, acylated steril- ⁇ -glucosides and other inducers.
- the present invention relates to a method of treating, preventing and/or prophylaxis of multiple sclerosis and/or one or more of its symptoms, which comprises administering to a subject an active substance that is somatotropin and/or insulin-like growth factor 1 (IGF-1) and/or their physiological inducers selected from the group consisting of arginine, lysine, glutamine and an acylated steril- ⁇ -glucoside, or a composition containing the specified active substance, in a therapeutically effective amount.
- IGF-1 insulin-like growth factor 1
- a composition comprising one or more active substances according to the invention is administered to the subject.
- several compositions are administered to the subject comprising the selected active substances of the invention. However, they can be introduced simultaneously, sequentially or separately.
- Treatment of a subject suffering from multiple sclerosis is not necessarily limited to the administration of the active substances or compositions of the invention; any other therapeutic treatment known to specialists can be used, including other active substances, in particular interferon- ⁇ -1b.
- This substance may be included in the compositions described above or administered separately, in particular as part of another pharmaceutical composition, simultaneously, sequentially or separately in relation to the active substances or compositions according to the invention.
- the amount of active substances administered by the invention is determined, as a rule, according to the body weight of a subject.
- Somatotropin is preferably used in an amount of from about 100 to 600 ⁇ g/kg of the body weight of a subject.
- this amount may be from 100, 125, 150, 175, 200, 225, 250, 275 or 300 ⁇ g/kg of the body weight of a subject and up to 600, 575, 550, 500, 475, 450, 425, 400, 375, 350 or 325 ⁇ g/kg of the body weight of a subject.
- the amount of somatotropin can be expressed in international units and range from 0.05 to 0.5 IU/kg of the body weight of a subject.
- this amount may be between 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 or 0.2 IU/kg of the body weight of a subject; and up to 0.49, 0.48, 0.47, 0.46, 0.45, 0.44, 0.43, 0.42, 0.41, 0.4, 0.39, 0.38, 0.37, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31 or 0.3 IU/kg of the body weight of a subject, including, in particular, the mentioned values.
- IGF-1 is preferably used in an amount of from 50 to 500 ⁇ g/kg of the body weight of a subject.
- this amount may be between 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160 , 165, 170, 175, 180, 185, 190, 195 or 200 ⁇ g/kg of the body weight of a subject; and up to 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 395, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, 330, 325, 320, 315, 310, 305 or 300 ⁇ g/kg of a subject’s body weight, including, in particular, the
- Physiological inducers are preferably used in an amount of from 1 ng/kg to 50 g/kg of the subject's body weight, depending on the type of inducer used. For example, this number can range from 1, 5, 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900 , 950 or 1000 ng/kg of the subject's body weight and up to 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000 or 2000 ng/kg of the subject's body weight, including, in particular, the mentioned values.
- the number of a physiological inducer can range from 1, 5, 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 ⁇ g/kg of the body weight of a subject and up to 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000 or 2000 ⁇ g/kg of the body weight of a subject, including, in particular, the mentioned values.
- the number can range from 1, 5, 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 mg/kg of the body weight of a subject and up to 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000 or 2000 mg/kg of the body weight of a subject.
- the number can be from 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4 or 2.5 g/kg of the body weight of a subject, and up to 5, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1 or 3.0 g/kg of the subject's body weight, including, in particular, the mentioned values.
- the number can range from 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or 40 and up to 50, 40, 30, 25, 20, 15, 10, 9, 8, 7 or 6 g/kg of the body weight of a subject, including, in particular, the mentioned values.
- the amount can be expressed in international units and range from 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 IU/kg of subject’s body weight to 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3 or 2 IU/kg of the body weight of a subject.
- arginine is administered in an amount of from 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400 or 450 mg/kg of the body weight of a subject and up to 500, 450, 400, 350, 300, 250, 200, 175, 150, 125, 100, 90, 80, 70 or 60 mg/kg of the body weight of a subject, including, in particular, the mentioned values.
- arginine is administered in an amount of from 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or 40 to 50, 40, 30, 25, 20, 15, 10, 9, 8, 7 or 6 g/kg of the body weight of a subject, including, in particular, the mentioned values.
- glutamine or lysine is administered in an amount of from 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250 or 300 mg/kg of the body weight of a subject and up to 350, 300, 250, 200, 175, 150, 125, 100, 90, 80, 70 or 60 mg/kg of the body weight of a subject, including, in particular, the mentioned values.
- acylated steril- ⁇ -glucoside is administered in an amount of from 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, or 1.5 mg/kg of the body weight of a subject, and up to 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2 or 0.1 mg/kg of the body weight of a subject, including, in particular, the mentioned values.
- the frequency of administration can be both reduced and increased.
- the frequency of administration can be reduced to 1 time in 2 days, 1 time in 3 days, 1 time in 4 days, 1 time in 5 days, 1 time in 6 days or 1 time in a week.
- the frequency can be increased to more than twice a day, for example 3, 4 or 5 times a day.
- the duration of administration of the active substances or compositions according to the invention is preferably from 10 to 60 days, for example from 10, 14, 21, 28 days and/or up to 56, 49, 42, 35, 30 days. Of course, depending on the severity of the therapeutic effect and possible side effects, the duration of treatment can be either reduced or increased relative to the mentioned values.
- the treatment may include several courses of administration of the active substances or compositions according to the invention or their essentially permanent administration.
- the exact dosage will depend on the purpose of the treatment and should be determined by the attending doctor with the help of well-known recommendations.
- the amount of therapeutic agent that is effective in alleviating a particular disease or condition may change according to several factors, such as the status of the disease, the age and weight of the patient, and others.
- the dosage may, if necessary, be corrected directly during treatment, depending on the severity of the therapeutic effect and side effects.
- the amount of somatotropin and/or IGF-1, and/or their physiological inducers in the compositions for use according to the invention can vary widely depending on the desired dosage form.
- the content of active substances in the compositions of the invention can be selected based on the approximate doses specified above, so that the finished dosage form ensures the easiest adherence of the patient to the prescribed treatment regimen.
- EAE Experimental allergic encephalomyelitis
- an encephalitogenic emulsion is obtained (homogenate of homologous brain of animals in a complete Freund's adjuvant), which is injected into the pads of hind paws of Guinea pigs (Abdurasulova I.N., Serdyuk S. ⁇ ., Gmiro V.E. 2007. // Neuroimmunology. V, N 1. P.4-10).
- the neurological status of the animals was evaluated daily. The time of the disease onset, the severity of neurological disorders, which was scored according to the clinical index, and lethal cases were recorded.
- the clinical index was determined by the intensity and prevalence of neurological manifestations: muscular weakness of one limb – 0.5 point, paresis - 1 point, paralysis – 1.5. If several limbs were affected, points were summed up. If there were additional symptoms (paresis of the sphincters), one point was added for every symptom. The absence of visible disorders was taken as 0 points, in the case of death – 6 points.
- somatotropin Four IU of somatotropin were administered to 16 subjects with an average weight of 70 kg, suffering from multiple sclerosis. The composition was administered daily in the morning 1 hour before meals. Before treatment and throughout the study period subjects were surveyed, assessing subjective symptoms on a 10-point scale, when a score of 10 is corresponding to the strongest symptom manifestation, and a score of 1 – the least weak symptom manifestation.
- somatotropin As can be seen from the results of the study, the introduction of somatotropin at a dose of approximately 0.05 IU/kg/day significantly reduced the degree of disease symptoms manifestations, starting from the first week of treatment; by the end of the fifth week of treatment, manifestations of dizziness, irritability, depression, numbness of the limbs were reduced to a minimum, the symptoms associated with fatigue and walking were significantly reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des méthodes de traitement de la sclérose en plaques par injection de somatotropine à un sujet en ayant besoin, en une quantité de 0,05 à 0,5 IU/kg de poids corporel du sujet à raison d'une ou de deux fois par jour, ou par injection ou administration par voie orale du facteur de croissance 1 analogue à l'insuline (IGF-1) en une quantité de 50 à 500 µg/kg de poids corporel du sujet à raison d'une ou de deux fois par jour, ou par administration d'un inducteur physiologique de somatotropine et/ou d'IGF-1 en une quantité thérapeutiquement efficace. Ces méthodes sont efficaces et sûres en termes d'effets secondaires. L'utilisation thérapeutique appropriée des substances actives selon l'invention est en outre décrite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017140515A RU2721282C2 (ru) | 2017-11-21 | 2017-11-21 | Способ лечения рассеянного склероза (варианты) |
RU2017140515 | 2017-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019103660A1 true WO2019103660A1 (fr) | 2019-05-31 |
Family
ID=66630780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2018/050142 WO2019103660A1 (fr) | 2017-11-21 | 2018-11-18 | Méthode de traitement de la sclérose en plaques (et variantes) |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2721282C2 (fr) |
WO (1) | WO2019103660A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116059213A (zh) * | 2023-03-29 | 2023-05-05 | 信义核新(北京)生物科技有限公司 | 一种化合物及其盐在癌症治疗药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
US20010012832A1 (en) * | 1999-08-25 | 2001-08-09 | Chein Edmund Y.M. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
RU2384345C2 (ru) * | 2004-06-04 | 2010-03-20 | Дженентек, Инк. | Способ лечения рассеянного склероза |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003103608A2 (fr) * | 2002-06-11 | 2003-12-18 | The Burnham Institute | Synergie neuroprotectrice de l'erythropoietine et du facteur de croissance semblable a l'insuline |
RU2011111391A (ru) * | 2008-08-28 | 2012-10-10 | Эбботт Байотерапьютикс Корп. (Us) | Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r |
PE20120332A1 (es) * | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
-
2017
- 2017-11-21 RU RU2017140515A patent/RU2721282C2/ru active
-
2018
- 2018-11-18 WO PCT/RU2018/050142 patent/WO2019103660A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
US20010012832A1 (en) * | 1999-08-25 | 2001-08-09 | Chein Edmund Y.M. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
RU2384345C2 (ru) * | 2004-06-04 | 2010-03-20 | Дженентек, Инк. | Способ лечения рассеянного склероза |
Non-Patent Citations (1)
Title |
---|
DASHPUTRE A.A. ET AL.: "Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis", JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, vol. 23, no. 6, 2017, pages 666 - 676, XP055619532 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116059213A (zh) * | 2023-03-29 | 2023-05-05 | 信义核新(北京)生物科技有限公司 | 一种化合物及其盐在癌症治疗药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
RU2017140515A (ru) | 2019-05-21 |
RU2721282C2 (ru) | 2020-05-18 |
RU2017140515A3 (fr) | 2019-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030152552A1 (en) | Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases | |
JP6680760B2 (ja) | アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用 | |
JP5954736B2 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
JP6266811B2 (ja) | 血管新生病の免疫療法 | |
KR20160120735A (ko) | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 | |
EA009939B1 (ru) | Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза | |
HU229045B1 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
JP5646617B2 (ja) | 多発性硬化症の治療のための組成物および方法 | |
RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
US20160271221A1 (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
Sabatino et al. | Impact of IL-9 and IL-33 in mast cells | |
JP6262661B2 (ja) | 筋萎縮性側索硬化症治療剤 | |
CN112336862B (zh) | β3-肾上腺素能受体激动剂在制备治疗神经系统疾病的药物中的应用 | |
KR20070004781A (ko) | 인터페론-타우를 포함하는 약학적 조성물 | |
WO2019103660A1 (fr) | Méthode de traitement de la sclérose en plaques (et variantes) | |
US20090068143A1 (en) | Orally effective cannabinoid analogs | |
CN112203675A (zh) | 用于改善虚弱和衰老的方法 | |
CN116019813A (zh) | Vesatolimod在制备预防和/或治疗中枢神经系统疾病的药物中的应用 | |
JP6987271B2 (ja) | 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 | |
RU2597795C2 (ru) | Ингибитор скопления жидкости в полостях организма | |
WO2011156900A2 (fr) | Composés, compositions et procédés pour traiter la sclérose en plaques | |
CN108853483B (zh) | 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途 | |
JP2023094736A (ja) | 疼痛治療薬 | |
RU2193883C1 (ru) | Лекарственный препарат и способ его получения | |
KR20240041399A (ko) | 항암 활성을 갖는 신규한 펩타이드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18880324 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18880324 Country of ref document: EP Kind code of ref document: A1 |